Case report
(HU), interferon alpha or courses of low-dose cytosine
We report a young man with an atypic course of HES arabinoside. including absence of multiorgan dysfunction, severe hyperIn July 1992, the patient was admitted with severe hypercalcemia with osteolytic lesions and transformation into calcemia (3.7 mmol/l) with osteolytic and osteosclerosing marked myelofibrosis, who underwent allogeneic bone lesions revealed on pelvic and chest X-rays. The echocardimarrow transplantation (BMT).
ogram showed mild mitral regurgitation without damage to the atrio-ventricular valves and without cardiac failure. Electromyogram showed no peripheral neuropathy. The WBC count was 22.8 ϫ 10 9 /l with 64% eosinophils, Hb was 8.8 g/dl and platelet count 116 ϫ 10 9 /l. The serum parathyroïd hormone (PHT) level was 72.5 pg/ml (N: 15-60). Bone marrow biopsy was hypercellular and showed advanced myelofibrosis. Cytogenetic analysis remained normal. geneic BMT was performed on October 1992 after splen-ectomy. Histologic analysis of the spleen revealed eosinophilic myeloid metaplasia. The donor was sex-mismatched, ABO matched and aged 46 years. Conditioning consisted of total body irradiation (12 Gy in 6 fractions) and cyclophosphamide (120 mg/kg over 2 days). Graft-versus-host (GVHD) and veno-occlusive disease (VOD) prophylaxes were with cyclosporin A + short methotrexate and alprostadil, respectively. Hematologic recovery was prompt with a polymorphonuclear count greater than 500/mm 3 on day 16 and stable platelet engraftment on day 15. The patient did not develop acute GVHD but limited chronic GVHD characterized by persistent lichenoid oral changes, was observed. BMT was first complicated on day 90 by a cerebral abscess of unknown etiology which resolved after treatment with broad-spectrum antibiotics including anti-
toxoplasmic agents, and on day 210, by a cytomegalovirus and resolved within 10 days on high-dose acyclovir.
174-RF DNA HaeIII digest. The products were electrophoresed on a 8% polyacrylamide gel for 1 h at 160 V.
In January 1996, 40 months after transplantation, the WBC count rose to 15.6 ϫ 10 9 /l with 28% eosinophils and the platelet count decreased to 110 ϫ 10 9 /l. The patient remained asymptomatic. Cytogenetic analysis showed cases, HES was uncontrolled with corticosteroids and hydroxyurea. These two treatments and an attempt with interabnormalities including t(2;8) (q22;p23) and t(1;9) (q31;q11). HU therapy has been started again and the feron therapy led to partial remission in our patient but did not prevent transformation into myelofibrosis. patient is alive and well 44 months post-BMT.
Although repeated examination of a sufficient number of mitoses never detected any male cells, Y DNA chromoEvaluation of the response somal amplification has shown an increasing signal since the 24th month post-BMT. Since this PCR analysis was In order to evaluate the residual disease, markers of HES and chimerism were studied at different times after BMT.
performed on a blood sample, contamination by recipient non-hematopoietic cells is unlikely. To the best of our Eosinophil counts and serum vitamin B12 levels decreased dramatically from high to normal and stable levknowledge, no other case of relapse after BMT has been reported in HES patients. els in 2-6 months after BMT. These two parameters and the serum alkaline phophatase levels remained completely
As PCR assay of Y chromosomal DNA was highly positive 6 months before the relapse, the predictive value of normal until relapse.
The pelvic X-ray revealed resolution of osteolytic and this analysis has to be considered. 6 The hypothesis that clonal expansion of a lymphocyte osteosclerosing lesions. Magnetic resonance imaging showed the disappearence of bone lesions 12 months after subset could 'drive' some HES has been suggested. 7 Although our patient has not been examined for an underly-BMT. Bone marrow examination showed persistent hypocellularity without resolution of myelofibrosis. Surprising proliferation of clonal T cells, the cytogenetic analysis obtained from early spontaneous marrow mitoses suggests ingly, bone marrow scintigraphy revealed axial hematopoiesis localized to the skull and backbone.
an eosinophil lineage origin. HES is very uncommonly associated with hypercalceChimerism was assessed by means of cytogenetic analysis and Y chromosomal DNA-specific repeat sequence mia. The serum PTH level was elevated in this patient but the pathogenic mechanism has not been precisely investiamplification by PCR assay. 2 Repeated karyotypes on BM cells were performed 1, 7, 15, 20 and 34 months post-BMT gated. However, in other malignancies such as chronic myelogenous leukemia (CML), ectopic production of PTH and showed only 46,XX mitoses. PCR analysis was carried out from peripheral blood mononuclear cells and showed and secretion of osteoclast activating factors have been implicated in the pathogenesis of hypercalcemia. 8 a decreasing signal until 19 months post-BMT followed by the reappearance of a high signal 34 months after transplanThe course of HES is very heterogeneous. Patients with a poor prognosis, for example with cardiac and neurologic tation (Figure 1) . manifestations or with bone marrow fibrosis with or without excess of blast cells, should be considered for allogeneic BMT.
Discussion
However, as occurred in this case, relapse may occur in long-term survivors after transplant. As in CML patients 9 Allogeneic BMT has been used in very few patients with HES. [3] [4] [5] The characteristics of these transplants are donor lymphocyte transfusions may eradicate clonal cells when minimal residual disease is detected by cytogenetic presented in Table 1 . No cases of transplantation with advanced myelofibrosis have been reported. In all of these or PCR analyses. We did not undertake this cellular therapy 
